Imunon, Inc. (NASDAQ:IMNN) Stock Short Interest Report for October

Imunon, Inc. (NASDAQ:IMNN) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 62,366 shares, a drop of 64.0% from the September 30th total of 173,197 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average daily volume of 92,780 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Imunon presently has an average rating of “Hold” and an average price target of $10.00.

Imunon Stock Up 9.2%

Shares of IMNN stock traded up $0.08 during mid-day trading on Friday, hitting $0.91. 131,494 shares of the stock traded hands, compared to its average volume of 119,952. The stock has a market cap of $5.11 million, a P/E ratio of -0.24 and a beta of 2.01. The stock’s fifty day moving average is $1.31 and its two-hundred day moving average is $2.24. Imunon has a 52-week low of $0.81 and a 52-week high of $4.67. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.82 and a quick ratio of 1.82.

Imunon (NASDAQ:IMNN) last posted its earnings results on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.33. Equities analysts predict that Imunon will post -2.37 EPS for the current year.

Imunon Company Profile

Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.

Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.